The dual specificity phosphatase 2 gene is hypermethylated in human cancer and regulated by epigenetic mechanisms

Tanja Haag¹, Antje M. Richter¹, Martin B. Schneider¹, Adriana P. Jiménez¹ and Reinhard H. Dammann¹,2*

Abstract

Background: Dual specificity phosphatases are a class of tumor-associated proteins involved in the negative regulation of the MAP kinase pathway. Downregulation of the dual specificity phosphatase 2 (DUSP2) has been reported in cancer. Epigenetic silencing of tumor suppressor genes by abnormal promoter methylation is a frequent mechanism in oncogenesis. It has been shown that the epigenetic factor CTCF is involved in the regulation of tumor suppressor genes.

Methods: We analyzed the promoter hypermethylation of DUSP2 in human cancer, including primary Merkel cell carcinoma by bisulfite restriction analysis and pyrosequencing. Moreover we analyzed the impact of a DNA methyltransferase inhibitor (5-Aza-dC) and CTCF on the epigenetic regulation of DUSP2 by qRT-PCR, promoter assay, chromatin immuno-precipitation and methylation analysis.

Results: Here we report a significant tumor-specific hypermethylation of DUSP2 in primary Merkel cell carcinoma (p = 0.05). An increase in methylation of DUSP2 was also found in 17 out of 24 (71 %) cancer cell lines, including skin and lung cancer. Treatment of cancer cells with 5-Aza-dC induced DUSP2 expression by its promoter demethylation, Additionally we observed that CTCF induces DUSP2 expression in cell lines that exhibit silencing of DUSP2. This reactivation was accompanied by increased CTCF binding and demethylation of the DUSP2 promoter.

Conclusions: Our data show that aberrant epigenetic inactivation of DUSP2 occurs in carcinogenesis and that CTCF is involved in the epigenetic regulation of DUSP2 expression.

Keywords: Cancer, Dual specificity phosphatase 2, Epigenetic, Merkel cell carcinoma, CTCF, DNA methylation

Background

Dual specificity phosphatases (DUSPs) are negative regulators of mitogen-activated protein kinases (MAPK) that regulate proliferative signaling pathways, which are often activated in cancer [1–3]. DUSP2 encodes a dual-specificity phosphatase that inactivates ERK1/2 and p38 MAPK [4, 5]. DUSP2 has also been found to regulate p53- and E2F1-regulated apoptosis [6, 7]. Previously it has been reported that DUSP2 expression is markedly reduced or completely absent in many human cancers [8, 9].

Epigenetic silencing of tumor suppressor genes (TSG) is one of the most relevant molecular alteration that occurs during carcinogenesis [10]. Promoter hypermethylation of TSG occurs in cancer through methylation at the DNA level at C5 of cytosine (5mC), when found as a di-nucleotides with guanine. DNA methylation in CpG islands of TSG leads to epigenetic silencing of the according transcript [11, 12]. The ten-eleven-translocation methylcytosine dioxygenases (TET1-3) catalyze the oxidation of 5mC and generate cytosine derivatives including 5-hydroxymethylcytosine (5hmC) [13, 14]. TET proteins are involved in diverse biological processes, as the zygotic epigenetic reprogramming, hematopoiesis and the development of leukemia [15–17]. The frequency of 5hmC suggests that these modified cytosine bases play
an important role in epigenetic gene regulation [18]. Aberrant levels of 5hmC have been reported in human cancer [19, 20]. Recently it has been shown that TET proteins bind the CCCTC binding factor (CTCF) [21]. CTCF is associated with altered expression of tumor suppressor genes, such as E-cadherin (CDH1), retinoblastoma 1, RASSF1A, CDKN2A/p16 and TP53 [22–25]. It has also been postulated, that CTCF itself acts as a tumor suppressor [26, 27].

Here we analyzed the epigenetic inactivation and regulation of the dual specificity phosphate 2 (DUSP2) in human cancers. Our data show that DUSP2 is aberrantly methylated in primary Merkel cell cancer and in different human cancer cell lines. Moreover, we observed that 5-Aza-dC and CTCF induce DUSP2 expression by its promoter demethylation.

Methods

Primary tissues and cell lines

The analyzed primary tissues include 22 Merkel cell carcinoma [28, 29], 20 pheochromocytoma [30, 31], six small cell lung cancer [32], 12 breast carcinoma [25, 33] and 12 benign nevus cell nevi [34]. RNA samples from normal tissues (liver, breast, kidney and lung) were obtained from Agilent Technologies (Santa Clara, USA). All patients signed informed consent at initial clinical investigation. The study was approved by local ethic committees (City of Hope Medical Center, Duarte, USA or Martin-Luther University, Halle, Germany). All cell lines were cultured in a humidified atmosphere (37 °C) with 5 % CO2 and 1× Penicillin/Streptomycin in according medium. Cells were transfected with 4 μg of constructs on 3.5 cm plates, using Polyethylenimine or X-tremeGENE HP (Roche Applied Science, Germany). TREx293 cells, that stably express the Tet repressor (LifeTechnologies), were transfected with the expression vector pcDNA4TO-CTCF (Stealth siRNA), HSS116455 (Stealth siRNA), HSS116456 (Stealth siRNA), HSS173820 (Stealth siRNA), HSS173821 (Stealth siRNA), HSS116457 (Stealth siRNA), HSS116458 (Stealth siRNA), HSS116459 (Stealth siRNA), HSS116460 (Stealth siRNA) and have been characterized previously [37, 38]. Five small interfering RNAs against CTCF: HSS173820 (Stealth siRNA), HSS116456 (Stealth siRNA), HSS11 6455 (Stealth siRNA), siCTCF1: UCACCCUCCUCAG GAUCACCUUAA, siCTCF2: GAUGCGCUCUAA GAAAGAA and a control siRNA: CUACGAUGAAG CACUAUUATT were obtained from Invitrogen (Carlsbad, CA, USA) and have been characterized previously [37, 38]. Cells were transfected with a pool of five specific siRNAs against CTCF or a control siRNA according to the manufacturer manual using Lipofectamin RNAiMax (Invitrogen). Five small interfering RNAs against CTCF: HSS173820 (Stealth siRNA), HSS116456 (Stealth siRNA), HSS11 6455 (Stealth siRNA), siCTCF1: UCACCCUCCUCAG GAUCACCUUAA, siCTCF2: GAUGCGCUCUAA GAAAGAA and a control siRNA: CUACGAUGAAG CACUAUUATT were obtained from Invitrogen (Carlsbad, CA, USA) and have been characterized previously [37, 38]. Cells were transfected with a pool of five specific siRNAs against CTCF or a control siRNA according to the manufacturer manual using Lipofectamin RNAiMax from Invitrogen (Carlsbad, CA, USA) on two consecutive days and incubated for a total of 96 h. RNA and protein was isolated.

Expression analysis

RNA was isolated using the Isol-RNA lysis procedure (5′Prime). 25 μg of breast, kidney, liver and lung RNA of normal human samples were obtained from Agilent Technologies (Santa Clara, CA, USA). RNA was DNase (Fermentas GmbH, St.Leon-Rot, Germany) digested and then reversely transcribed [36]. RT-PCR was performed with primers listed in Additional file 1: Table S1. Quantitative PCR (qRT-PCR) was performed in triplicates with SYBR® Select Master Mix (Life Technologies) using Rotor-Gene 3000 (Corbett Research, Qiagen).

Promoter assay

The DUSP2 promoter was amplified with primers DUSP2BglIIU1: CAGATCTGAGTGGCTGGGACAG GTCA and DUSP2PromL1: CAGACGACGCTTGCG TTCCG from genomic DNA. The 454 bp promoter fragment was cloned into the BglII sites of pRLnull (Promega, Mannheim, Germany) and sequenced. In vitro methylation of the promoter construct was done with M.SsI methylase (NEB, Frankfurt, Germany). HEK293 were transfected with 1 μg of pRL-DUSP2 promoter construct and 0.35 μg of pGL3 control vector (Promega, Mannheim, Germany). Cells were isolated 24 h after transfection and studied using Dual-Luciferase Reporter Assay (Promega, Mannheim, Germany).

Depletion of CTCF by RNAi

Methylation analysis

DNA was isolated by phenol-chloroform extraction and then bisulfite treated prior to combined bisulfite restriction analysis (COBRA) and pyrosequencing [35]. 200 ng were subsequently used for semi nested PCR with primer DUSP2BSU2 (GGGATTTGTATTTGGTGTTGTTT) and DUSP2BSL2 (CCTCCAACCCCATAAACCACC) in a first PCR. For the second PCR DUSP2BSU1 (GTTTTTTTTYGGTGTGTTGGTTTT) and the 5′-biotinylated primer DUSP2BSBIO (CCTCCAACCCCATAAACCACC) were used. Products were digested with 0.5 μl TagI (Fermentas) 1 h at 65 °C and resolved on 2 % TBE agarose gel. Methylation status was quantified utilizing the primer DUSP2BSSeq1 (TTTTGTTTTTTT GTTTTTTTTTTTGTATGTTGTTTT) and PyroMark Q24 (Qiagen). Five CpGs are included in the analyzed region with primer DUSP2BSSeq1 and seven in the region analyzed with primer DUSP2BSSeq2. For in vitro methylation of genomic DNA we used M.SsI methylase (NEB).

Chromatin immunoprecipitation (ChIP)

Cells were fixed using 37 % formaldehyde (CalBiochem) with a final concentration of 1 % for 10 min at room temperature. Incubation of 1/7 volume of 1 M glycine for 5 min stopped the fixation process. Cells were washed with PBS and harvested in PBS + 1 mM PMSF.

M. Haag et al. BMC Cancer (2016) 16:49
After centrifugation for 2 min at 2000 rpm at 4 °C the supernatant was removed and cells were lysed using 1 ml SDS lysis buffer (0,5 % SDS, 10 mM EDTA, 50 mM Tris HCl pH 8.1) supplemented with protease inhibitors (Complete Mini, Roche) per 10⁷ cells for 10 min on ice. After sonification (400-800 bp) the samples were centrifuged for 10 min at 4 °C and maximum speed. The supernatant was diluted 1:10 with dilution buffer (0,01 % SDS, 1,1 % Triton X-100, 1,2 mM EDTA, 16,7 mM Tris/ HCl pH 8.1, 167 mM NaCl) and 1 ml of the dilution was used for each ChIP. 10 % of the chromatin used for one ChIP was preserved as an input sample and stored at -20 °C. The lystate was pre-cleared by rotation at 4 °C for 2 h using 1 ml of the dilution and 20 μl ProteinG Plus/ ProteinA Agarose (Calbiochem). After centrifugation at 4 °C for 1 min at 2000 rpm the supernatant was incubated with the corresponding antibody: IgG (46540; Santa Cruz Biotechnologie), Histon H3 (1791; Abcam), α-CTCF-(N2.2, [39]) rotating overnight at 4 °C. Binding of the immune-complexes occurs afterwards by incubation of the chromatin with 20 μl of ProteinG Plus/Protein A agarose for 2 h at 4 °C. After incubation the beads were washed for 5 min rotating at 4 °C one time with low salt buffer (0,05 % SDS, 1 % TritonX100, 2 mM EDTA, 20 mM Tris/HCl pH 8.1, 150 mM NaCl), one time with high salt buffer (0,05 % SDS, 1 % TritonX100, 2 mM EDTA, 20 mM Tris/HCl pH 8.1, 500 mM NaCl), one time with LiCl buffer (0,25 M LiCl, 1 % NP40, 1 % Deoxycholat, 1 mM EDTA, 10 mM Tris/HCl pH 8.1) and two times with TE buffer (10 mM Tris, 1 mM EDTA pH 8.0). Chromatin bound to beads and input material were resuspended in 100 μl TE buffer, 1 μl of 10 mg/ml RNase was added followed by an incubation of 30 min at 37 °C. 5 μl of 10 % SDS, 1 μl of 20 mg/ml Proteinase K was added and incubated for further 2-4 h at 37 °C. The reverse crosslink was performed by incubating the samples over night at 65 °C. DNA was recovered by using QIAquick PCR Purification Kit (Qiagen) and PCR amplification with the following primer: DUSP2CIPL1: TTGAGGCGCGGTTCGCTACAG AG, DUSP2CIPL1: GCCTCCGCTGTTCCTCCACCCAG TC, DUSP2CIPL2: GGGGGCGCCAAAAACCGAGGGA, DUSP2CIPL2: CCGGGGCACCATAAAGCGGCA, DUSP2CIPL3: GCCACGTTCAC CTCCTGAGTGTCTC, DUSP2CIPL3: GCTCGAGCAAGTGGCCGACA. PCR was done with U1/L1 (233 bp), U2/L2 (236 bp) and U3/L3 (120 bp) for positive site, DUSP2 promoter site and negative site, respectively. Quantitative PCR was performed in triplicates with SYBR® Select Master Mix (Life Technologies) using Rotor-Gene 3000 (Corbett Research, Qiagen).

Methylated DNA-immunoprecipitation (MeDIP)
MeDIP was performed according to the protocol of Mohn et al. [40] with antibodies: IgG (46540; Santa Cruz Biotechnologie), 5mC (MAb-081-010; Diagenode) and 5hmC (MAb-31HMC-020; Diagenode). The following primers were used for semi quantitative PCR amplification: DUSP2CIPL2: GGGTGGGCGCCAAAAACCGAGGGA, DUSP2CIPL2: CCGGGGCACCATAAAGCGGCA, DUSP2CIPL2: CCTTCCTTCTGGGCATGGAGT C, DUSP2CIPL2: CCGAGTCCTTGGCGCTACAGAGGA.

Western blot
Cell lysates were resolved in SDS-PAGE, immuno-blotted, and probed with primary anti-CTCF (N2.2) and anti-GAPDH antibody (GAPDH rabbit polyclonal IgG FL-335, Santa Cruz) [39]. Afterwards an incubation with HRP-coupled secondary antibodies followed. Immunocomplexes were detected by enhanced chemiluminescence reagent (Western Chemiluminescent Immobilon HRP-Substrate, Millipore) according to the manufacturer's instructions.

Constructs
CTCF and BORIS were generous gifts from Rainer Renkawitz (Justus-Liebig-University, Giessen, Germany) and deletions and mutations were generated with QuikChange Lightning Site-Directed Mutagenesis Kit (Promega, Heidelberg, Germany) with the primers listed in Additional file 2: Table S2.

Statistical evaluation
Statistical analysis was performed using Excel (Microsoft, Redmond, USA) and GraphPad Quick Calcs (GraphPad Software, La Jolla, USA). Data are represented as mean ± standard deviation. Unpaired t-test was used to determine significant differences between groups. For statistical analysis of methylation differences between Merkel cell carcinoma and benign controls a two tailed Fisher exact test was performed. All reported p-values are considered significant for p ≤ 0.05.

Results
Aberrant promoter methylation of DUSP2 in human cancer
Previously it has been shown that expression of the MAPK-specific phosphatase DUSP2 is markedly reduced or completely absent in many human cancers and that its level of expression inversely correlates with cancer malignancy [8]. Here we aimed to dissect the epigenetic mechanisms involved in the aberrant downregulation of DUSP2 in carcinogenesis. DUSP2 is located on 2q11.2 (Fig. 1a) and contains a 1011 bp CpG island in its promoter region (chr2: 96810444-96811454, UCSC genome browser). We analyzed the promoter hypermethylation of DUSP2 in primary tumors including Merkel cell carcinoma (MCC), pheochromocytoma, small cell lung cancer and breast carcinoma by COBRA (Fig. 1 and Additional file 3: Figure S1). In 12 breast carcinoma, 20
pheochromocytoma and six small cell lung cancer samples the \textit{DUSP2} promoter was unmethylated (Additional file 3: Figure S1). Interestingly, 10 out of 22 (45 \%) Merkel cell carcinoma showed a \textit{DUSP2} hypermethylation (Fig. 1b). MCC is a rare but aggressive cutaneous malignancy. In the control tissue (benign nevus cell nevi) only one out of 12 (8 \%) analyzed samples exhibited a \textit{DUSP2} hypermethylation (NCN12; Fig. 1b). Thus in MCC a significant tumor-specific hypermethylation of \textit{DUSP2} was detected ($p = 0.05$, two tailed Fisher exact test).

To reveal the epigenetic status of \textit{DUSP2} in human cancers in more detail, we have analyzed the methylation of its promoter in several human cancer cell lines by COBRA (Fig. 2a) and by pyrosequencing (Fig. 2b). Human fibroblasts (HF53) and the HB2 mammary luminal epithelial cells are unmethylated (methylation level <5 \%) (Fig. 2a and b). We detected increased \textit{DUSP2} methylation (level ≥5 \%) in lung cancer (A427, H322, A549), breast cancer (MCF-7, ZR75-1), melanoma (SKMel13, IGR1, buf1280, SKMel28, MeWo), ovarian cancer (Skov, Ovar, ES2, OAW42), hepatocarcinoma (Hep2G) and sarcoma (LMS6/93, U2OS) cell lines (Fig. 2a and b). Lung cancer cell lines H358 and HTB171, melanoma C8161, ovarian cancer CAOV3, pancreatic cancer PaCa2, thyroid cancer FTC133 and HeLa were rather unmethylated (<5 \%). Furthermore the embryonic kidney cell line

---

**Fig. 1** Hypermethylation of \textit{DUSP2} in primary Merkel cell carcinoma (MCC). a Structure of the \textit{DUSP2} CpG island promoter on chromosome 2q11.2. Vertical lines indicate CpGs and the transcriptional start site is marked. A CTCF motif sequence (GGCAGAGCA; CTCFBSDB2.0) is marked \[47\]. Primers used for COBRA and sequencing (Seq1 and Seq2) are depicted by arrows. TaqI restriction sites for COBRA and CpGs analyzed by pyrosequencing are indicated. The 454 bp \textit{DUSP2} fragment for the luciferase promoter assay is indicated. b Methylation of \textit{DUSP2} in MCC (m = methylated). For COBRA bisulfite-treated DNA from MCC, benign nevus cell nevi (NCN) and in vitro methylated DNA (ivm) was amplified by semi-nested PCR. First and second PCR products are indicated (439 bp and 303 bp, respectively). Products were digested with TaqI (+) or mock digested (-) and resolved on 2 \% agarose gels with a 100 bp marker (M).
HEK293 showed an aberrant *DUSP2* promoter methylation (29 %). In summary, 17 out of 24 (71 %) human cancer cell lines exhibited increased *DUSP2* promoter methylation.

**Decreased expression of *DUSP2* is associated with its promoter hypermethylation**

To further analyze the impact of epigenetic regulation of *DUSP2* in carcinogenesis we investigated its expression in normal tissues and cancer cell lines (Fig. 3). *DUSP2* expression was found in normal breast, kidney, liver, lung tissues and in HEK293 cells (Fig. 3a). In HEK293 cells a genome wide expression array (human ST1.0 S, Affymetrix) detected a 0.02-fold reduced level of *DUSP2* compared to *beta-actin* [41]. We cloned a 454 bp fragment of the *DUSP2* promoter in a luciferase reporter system (Fig. 1a), in vitro methylated (ivm) the construct and analyzed its activity (Fig. 3b). Methylation of the *DUSP2* promoter construct significantly reduced its expression (Fig. 3b). In cancer cell lines (H322, ZR75-1) and HEK293 cells, that exhibit a methylated promoter, expression of *DUSP2* was reduced compared to HeLa and H358 cells, which harbor unmethylated promoter regions (Fig. 3c). H322, ZR75-1 and HEK293 cells were treated with 5-Aza-dC (Aza), a cytidine analogue that inhibits DNA methyltransferases and reactivates epigenetically inactivated TSG [42, 43]. After four days of Aza treatment an induced expression of *DUSP2* was found in H322, ZR75-1 and HEK293 cells (Fig. 3c). However, in HeLa and H358 cells, that harbor unmethylated *DUSP2* promoters, *DUSP2* expression was rather unaffected by Aza (Fig. 3c). For H322 cells the fourfold increased *DUSP2* expression after 5 μM Aza treatment was correlated with a significant 1.6-fold demethylation of seven analyzed CpGs at the *DUSP2* promoter (Fig. 3d and e). Thus, we observed a methylation dependent silencing of *DUSP2* in cancer cell lines, which was reversed by inhibiting DNA methylation.

**Regulation of *DUSP2* by the epigenetic factor CTCF**

It has been shown that the insulator binding protein CTCF is involved in the epigenetic regulation of tumor suppressor genes [22–25, 44, 45]. Wendt and Barksi et al. have reported that silencing of CTCF by RNA interference caused repression of *DUSP2* in HeLa cells [38, 46]. Database analysis of CTCF ChipSeq Encode data revealed that
CTCF binds at the DUSP2 promoter in HeLa cells (chr2: 96811040-96811190) and a search at the CTCFBSDB2.0 site identified a CTCF motif sequence (GGCAGAGCA chr2: 96811243-96811251) upstream of the DUSP2 transcription start site (Fig. 1a) [47]. To investigate the role of CTCF in the epigenetic regulation of DUSP2, we performed siRNA mediated knock down of CTCF in HEK293, HeLa and HTB171 cells (Fig. 4). In HEK293, a five-fold reduction of CTCF on RNA and protein levels was accomplished by transfection of CTCF-specific siRNA (Fig. 4a and b). This downregulation of CTCF resulted in a 2.5-fold reduction of DUSP2 level (Fig. 4a). Knock down of CTCF in HeLa and HTB171 cells induced a 1.7-fold reduction of DUSP2 (Fig. 4c).

Next, we tested the effect of CTCF overexpression in cancer cells (Fig. 4 and Additional file 4: Figure S2). In HEK293 and H322 cells that harbor a methylated DUSP2 promoter CTCF transfection resulted in a 1.4-
and 2-fold increased expression of DUSP2, respectively (Fig. 4d and e). In HeLa cells that exhibit an unmethylated promoter this CTCF-induced expression of DUSP2 was absent (Additional file 4: Figure S2A). The testis-specific paralogue of CTCF, termed CTCFL or BORIS was unable to induce DUSP2 expression in HEK293 cells (Additional file 4: Figure S2B). Previously, it has been reported that SUMOylation and PARylation of CTCF are involved in its regulatory function [23, 48, 49]. Therefore we generated different CTCF constructs that lack either the N- or C-terminal SUMOylation site (K > R substitution) at position 74 (CTCF-K > R74) and 691 (CTCF-K > R691), respectively or harbor a deletion of its PARylation sites from position 216 to 243 (CTCF-ΔPAR). Expression of the two SUMOylation-site deficient CTCF constructs in HEK293 and H322 cells resulted in a lack of DUSP2 induction compared to wildtype CTCF (Fig. 4d and e). Transfection of the PARylation site deficient CTCF construct (CTCF-ΔPAR) downregulated DUSP2 expression significantly (2.2- and 5.6-fold, respectively) compared to the vector control in HEK293 and H322 cells (Fig. 4d and e). Furthermore, we have generated a stable HEK293 cell line (CTCF-TREx293) that allows tetracycline-inducible CTCF expression (Fig. 4f and g).
Induction of CTCF in TREx293 cells resulted in 1.6-fold higher DUSP2 expression (Fig. 4f).

Increased CTCF binding at the DUSP2 promoter is associated with reduction in methylation levels and induced DUSP2 expression

To analyze the mechanism of CTCF regulated DUSP2 expression in detail, we analyzed the binding of CTCF at the DUSP2 locus in CTCF TREx293 cells by ChIP (Fig. 5a). Therefore, we utilized CTCF and histone H3 antibody and quantified the precipitation of the DUSP2 promoter, a bona fide CTCF target site at 1 kb downstream (positive site) and negative site 1 kb upstream of the DUSP2 transcriptional start site by qPCR. After CTCF induction we observed a significant 2.3-fold increased binding of CTCF at the DUSP2 promoter. Histone H3 binding and CTCF binding at the negative site were not altered. At the positive site binding of CTCF was significantly increased by 1.6 times after tetracycline-induced CTCF expression (Fig. 5a). Histone H3 levels were reduced after CTCF induction at the positive site (Fig. 5a).

Subsequently, we analyzed changes in DNA methylation after CTCF induction at the DUSP2 promoter (Fig. 5). Conventional bisulfite sequencing is not able to distinguish between 5-methylcytosine (5mC) or 5-hydroxy-methylcytosine (5hmC) levels. Therefore we precipitated different DNA regions with antibodies that bind 5mC or 5hmC in induced or uninduced CTCF TREx293 cells. Interestingly, after CTCF induction we observed a decrease in 5hmC-precipitated DUSP2 promoter sequences compared to a control locus control (chr5q14.1) (Fig. 5b). This result suggests that CTCF induces dehydroxymethylation of the DUSP2 promoter. To analyze the effect of CTCF on the DUSP2 promoter, we performed luciferase reporter assays (Fig. 5c). Therefore the DUSP2 promoter construct was in vitro methylated (ivm) and transfected together with CTCF in HEK293 cells. CTCF transfection significantly induced luciferase reporter activity of the unmethylated DUSP2 promoter (1.7-fold) and ivm DUSP2 promoter (1.4-fold) compared to the pEGFP control vector (Fig. 5c). Moreover CTCF induction in CTCF TREx293 cells resulted in a 1.7-fold (unmethylated) or 1.5-fold (ivm) increased DUSP2 promoter activity compared to uninduced cells (Fig. 5c). Taken together these data suggest that CTCF epigenetically activates DUSP2 expression.

Discussion

Previously it has been reported that DUSP2 expression is downregulated in many human cancers [8]. However the mechanism of its silencing was not analyzed in details. Deletion of the DUSP2 locus at 2q11.2 is rather infrequent in cancer. Here we show that the promoter of DUSP2 is hypermethylated in different human cancer cell lines including lung, breast and skin cancers and in HEK293 cells (Figs. 1 and 2). In primary Merkel cell cancer (MCC) we observed a significant tumor specific methylation of DUSP2. MCC is one of the most aggressive cancers of the skin and we have reported frequent hypermethylation of the Ras Association Family Members RASSF1A and RASSF10 in this tumor entity [28, 29]. Hypermethylation of DUSP2 and murine Dusp2 and has been reported in breast cancer cell lines, however methylation in primary human mammary tumors was absent [50], which was also observed in our study (Additional file 3: Figure S1). By inhibiting DNA methyltransferases with the cytidine analogue 5-aza-dC we found that the DUSP2 gene is epigenetically reactivated by its demethylation (Fig. 3). The promoter methylation of DUSP2 in HEK293 consists of 5mC and 5hmC epigenetic marks (Fig. 5). Additionally, we have revealed that CTCF reactivates DUSP2 and this is associated with demethylation of its CpG island promoter (Figs. 4 and 5b). CTCF is a DNA binding factor well known for its multiple functions in gene regulation. Depending on the participating genetic locus it is involved in transcriptional activation [51–53], transcriptional repression [54, 55] or enhancer blocking [56]. Here we show increased binding of CTCF to the DUSP2 promoter (Fig. 5a) and CTCF-dependent induction of the DUSP2 promoter activity (Fig. 5c). Thus it will be interesting to analyze the exact mechanism of CTCF induced DUSP2 expression and promoter dehydroxy-methylation in further details.

DUSP2 encodes a dual-specificity phosphatase that inactivates ERK1/2 and p38 MAPK [4, 5]. DUSP2 has also been found to regulate p53- and E2F1-regulated apoptosis [6, 7]. Dual-specificity phosphatases are negative regulators of the MAPK signal transduction, proliferative pathways that are often activated in cancers [1]. Down-regulation of DUSP2 was detected in human acute leukemia coupled with activation of MEK and hyperexpression of ERK [9]. Especially in acute myeloid leukemia, translocation and mutations of TET1 and TET2 gene are frequently observed [57–59]. Moreover it has been reported that CTCF binds TET proteins [21]. Thus it will be interesting to analyze if TET proteins are directly involved in the epigenetic regulation of DUSP2. Here we observed increased binding of CTCF to its target site in the DUSP2 promoter after CTCF induction (Fig. 5a). This binding may alter distinct TET- or DNMT-associated chromatin complexes at the DUSP2 promoter region involved in CTCF-regulated DNA methylation as previously reported [21, 25, 60, 61] and revealed in Fig. 5b. However CTCF-dependent regulation of DUSP2 may also involve its function in chromosome configuration, chromatin insulation or transcriptional regulation [62, 63].
Fig. 5 Epigenetic regulation of the DUSP2 promoter by CTCF.  

(a) Binding of CTCF at the DUSP2 promoter analyzed by quantitative ChIP. CTCF expression was induced in CTCF TREx293 cells by tetracycline (5 μg/ml) for 48 h and uninduced cells were used as control. The chromatin was prepared, precipitated with a CTCF-, histone H3- or control IgG-antibodies and amplified with gene specific primers for the DUSP2 promoter, a negative site and a bona fide positive site within the DUSP2 locus. CTCF binding was quantified by qPCR (triplicates from 2 independent experiments) and significance was calculated. Values of the precipitated sample were normalized to 1 % input (=1).

(b) Methyl-DNA immunoprecipitation (MeDIP) analysis of the DUSP2 promoter. MeDIP with 5mC- and 5hmC-antibodies was done with DNA from uninduced or induced CTCF TREx293 cells. The detection of the 5hmC and 5mC level was performed with semi-quantitative PCR of the DUSP2 promoter and a control locus. PCR products were separated together with a 100 bp marker (M) in 2 % agarose gel.

(c) Effect of CTCF on the DUSP2 promoter. A DUSP2 promoter fragment (454 bp) was cloned in the pRLnull vector and in vitro methylated (ivm). 2.7 μg DUSP2 promoter constructs (DUSP2-pr.) were transfected in HEK293 or CTCF TREx293 cells and GFP-CTCF or GFP vector (1 μg each) was co-transfected or CTCF was induced for 24 h, respectively. Expression of renilla luciferase was measured and normalized to the expression control vector or to the co-transfected firefly plasmid pGL3.1 (300 ng), respectively. Significance is indicated (t-test).
We also observed that the CTCF parologue CTCFL/BORIS was unable to reactivate DUSP2 expression (Additional file 4: Figure S2). Since the cancer-testis specific BORIS is aberrantly expressed in cancer, an oncogenic role for BORIS has been proposed [64, 65]. It was reported that CTCF, unlike BORIS, cannot bind to methylated binding sites [66]. Therefore, it is interesting to note that the CTCF consensus site in the DUSP2 promoter sequence lacks CpG sites (Fig. 1a) and ChIP data show an enhanced CTCF binding in CTCF induced TRex293 cells at this site (Fig. 5a). It was also postulated that CTCF itself acts as a tumor suppressor [26, 27]. CTCF contains a N-terminal PARylation site [49]. Here we observed that overexpression of CTCF lacking its PARylation site resulted in repression of DUSP2 expression in H322 and HEK293 cells (Fig. 4d and e). This result suggests that the PARylation site of CTCF is important for its activating function. It has been reported that defective CTCF PARylation and dissociation from the molecular chaperone nucleolin occurs in CDKN2A- and CDH1-silenced cells, abrogating its TSG function [23]. Using CTCF mutants, the requirement of PARylation for optimal CTCF function in transcriptional activation of the p19ARF promoter and inhibition of cell proliferation has been demonstrated [49]. In this model CTCF and Poly(ADP-ribose) polymerase 1 form functional complexes [49]. Furthermore, CTCF contains two SUMOylation sites [48]. Overexpression of the CTCF construct with mutated SUMOylation sites in the CTCF N-terminus or C-terminus resulted in a lack of DUSP2 reactivation in the lung cancer H322 and HEK293 cells (Fig. 4d and e). SUMOylation of CTCF has been associated with its tumor suppressive function in c-myc expression [48]. There is also a report that CTCF SUMOylation modulates a CTCF domain, which activates transcription and decondenses chromatin [67].

Conclusions
Downregulation of the negative regulator DUSP2 of the oncogenic MAPK signaling pathway has been reported in cancer. In the present study we have investigated the epigenetic regulation of DUSP2 in detail and we show that DUSP2 is epigenetically silenced by promoter methylation in human cancer. Especially in primary Merkel cell carcinoma a tumor-specific hypermethylation of DUSP2 was revealed. Thus it will be interesting to further analyzed primary tumor tissues regarding an aberrant DUSP2 promoter hypermethylation. Moreover our data indicate that the insulator-binding factor CTCF is involved in the epigenetic regulation of DUSP2. Further research will elucidate the exact mechanism of the CTCF-mediated induction of DUSP2.

Additional files

Additional file 1: Table S1. List of primers for RT-PCR. (DOCX 17 kb)
Additional file 2: Table S2. Primers for site directed mutagenesis of CTCF. (DOCX 47 kb)
Additional file 3: Figure S1. Four examples of methylation analysis of DUSP2 in primary pheochromocytomas (Pheo), small cell lung cancer (SCLC) and breast cancer (BrCa). (PDF 2955 kb)
Additional file 4: Figure S2. CTCF- and BORIS-dependent expression of DUSP2 in HeLa and HEK293 cells, respectively. (PDF 1891 kb)

Abbreviations
Aza: 5-aza-dC; COBRA: combined bisulfite restriction analysis; CTCF: CCCTC binding factor; DUSP2: dual specificity phosphatase 2; MCC: Merkel cell carcinoma.

Competing interests
The authors declare that they have no competing interests. The work was supported by grants (TRR81, LOEWE) from the DFG and Land Hessen to RHD. These organizations had no involvement in the study design, acquisition, analysis, data interpretation, writing of the manuscript and in the decision to submit the manuscript for publication.

Authors’ contributions
RHD has created the study. TH and RHD participated in the design of the study, TH, AMR, APJ and MBS acquired data. TH, MBS, AMR, APJ and RHD controlled analyzed and interpreted data. RHD and TH prepared the manuscript. TH, MBS, AMR, APJ and RHD read, corrected and approved the final manuscript.

Acknowledgements
The work was supported by grants (TRR81, LOEWE) from the DFG and Land Hessen to Reinhard Dammann. These organizations had no involvement in the study design, acquisition, analysis, data interpretation, writing of the manuscript and in the decision to submit the manuscript for publication.

Received: 28 September 2015 Accepted: 27 January 2016
Published online: 01 February 2016

References
1. Owens DM, Keyse SM. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene. 2007;26(22):3203–13.
2. Bermudez O, Pages G, Gimond C. The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. Am J Physiol Cell Physiol. 2010;299(2):C189–202.
3. Huang CY, Tan TH. DUSPs, to MAP kinases and beyond. Cell Biosci. 2012;2(12).
4. Rohan PJ, Davis P, Moskaluk CA, Keams M, Krutzsch H, Siebenlist U, et al. PAC-1: a mitogen-induced nuclear protein tyrosine phosphatase. Science. 1993;259(5102):1763–6.
5. Zhang Q, Muller M, Chen CH, Zeng L, Farooq A, Zhou MM. New insights into the catalytic activation of the MAP kinase phosphatase PAC-1 induced by its substrate MAPK ERK2 binding. J Mol Biol. 2005;354(4):777–88.
6. Wu J, Jin YJ, Calaf GM, Huang WL, Yin Y. PAC-1 is a direct transcription target of EZF-1 in apoptotic signaling. Oncogene. 2007;26(45):6526–35.
7. Yin Y, Liu YX, Jin YJ, Hall EJ, Barrett JC. PAC1 phosphatase is a transcription target of p53 in signalling apoptosis and growth suppression. Nature. 2003; 422(6931):527–31.
8. Lin SC, Chien CW, Lee JC, Yeh YC, Hsu KF, Lai YY, et al. Suppression of dual-specificity phosphatase-2 by hypoxia increases chemoresistance and malignancy in human cancer cells. J Clin Invest. 2011;121(5):1905–16.
9. Kim SC, Hahn JS, Min YH, Yoo NC, Ko YW, Lee WJ. Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: combined role of activation of MEK, hyp erexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase PAC1. Blood. 1999;93(11):3893–9.
10. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683–92.
11. Bergman Y, Cedar H. DNA methylation dynamics in health and disease. Nat Struct Mol Biol. 2013;20(3):274–81.
12. Taberlay PC, Jones PA. DNA methylation and cancer. Prog Drug Res. 2011; 67:1–23.
13. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Sweeney JA, et al. TET proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxycytosine. Science. 2011;336(6074):1100–3.

14. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324(5929):930–5.

15. Wu H, Zhang Y. Mechanisms and functions of TET protein-mediated 5-methylcytosine oxidation. Genes Dev. 2011;25(23):2436–52.

16. Pfeifer GP, Kadmans S, Jin SG. 5-Hydroxymethylcytosine and its potential role in development and cancer. Epigenetics. 2013;6(1):110.

17. Kraici S, Henri N. The nucleic DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science. 2009;324(5929):930–3.

18. Nestor CE, Ottaviano R, Reddington J, Spruol D, Reinhardt O, Dunican D, et al. Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. Genome Res. 2012;22(3):467–77.

19. Hafliger MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru L, et al. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancer. Oncotarget. 2012;3(18):6623–32.

20. Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, et al. Loss of 5-methylcytosine is an epigenetic hallmark of melanoma. Cell. 2012;150(6):1135–46.

21. Dubois-Chevallier J, Oger F, Reddington J, Spruol D, Reinhardt O, Dunican D, et al. A dynamic CTCF chromatin binding landscape promotes DNA hydroxymethylation and transcriptional induction of adipogenic differentiation. Nucleic Acids Res. 2014;42(17):10943–59.

22. Soto-Reyes E, Recillas-Targa F. Epigenetic regulation of the human p53 gene promoter by the CTCF transcription factor in transformed cell lines. Oncogene. 2010;29(15):2217–27.

23. Witcher M, Emerson BM. Epigenetic silencing of the p16(INK4a) tumor suppressor gene promoter hypermethylation is frequent in malignant melanoma of the skin but not in benign nevi. J Invest Dermatol. 2011;132(7):1574–81.

24. Haag T, Herkt CE, Walesch SK, Richter AM, Dammann RH. The apoptosis associated tyrosine kinase gene is frequently hypermethylated in human cancer and is regulated by epigenetic mechanisms. Genes Cancer. 2014;5(9-10):365–74.

25. Helmbold P, Richter AM, Walesch S, Haag T, Dammann RH. The association of 5-hydroxymethylcytosine with active histone modifications in human colorectal cancer cells is mediated via the histone variant H3K27me3. Nucleic Acids Res. 2014;42(19):11941–51.

26. Mohn F, Weber M, Schubeler D, Roloff TC. Methylated DNA immunoprecipitation (MeDIP). Methods Mol Biol. 2009;507:55–64.

27. Haag T. Epigenetic analysis of tumor suppressor genes and their regulation by CTCF. Giessen: Justus-Liebig-Universität Giessen; 2014.

28. Jones PA, Taylor SM. Cellular differentiation, cytokine analogs and DNA methylation. Cell. 1980;120:1(185):85–93.

29. Dammann R, Li C, Youm JM, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000;25(3):315–9.

30. Filipova GN, Qi CF, Ulmer JE, Moore JM, Ward MD, Hu Y, et al. Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter its DNA-binding specificity. Cancer Res. 2002;62(1):48–52.

31. Mendez-Catala CF, Grettson S, Vostrov A, Pugacheva E, Farrad I, Doo Y, et al. A novel mechanism for CTCF to maintain the epigenetic regulation of Bax in breast cancer cells. Neoplasia. 2013;15(8):898–912.

32. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, et al. High-resolution profiling of histone modifications in the human genome. Cell. 2007;129(4):823–37.

33. Ziebarth JD, Bhatchayaha A, Cui Y. CTCFBSID 2.0, a database for CTCF-binding sites and genome organization. Nucleic Acids Res. 2013;41(Database issue):D188–94.

34. Macpherson MS, Beatty LG, Zhou W, Du M, Sadowski PD. The CTCF insulator protein is posttranslationally modified by SUMO. Mol Cell Biol. 2002;22(9):745–54.

35. Farrad I, Rai S, Chernukhin I, Madic D, Yammine S, et al. Mutation analysis of the poly(ADP-ribosyl)ation sites of the transcription factor CTCF provides an insight into the mechanism of its regulation by poly(ADP-)ribosylation. Mol Cell Biol. 2010;30(3):1199–216.

36. Demirkan B, Dyr LM, Gerace M, Lobenhoffer EK, Robertson KD, Brown KD. Comparative epigenomics of human and mouse mammary tumours. Genes Chromosomes Cancer. 2009;48(1):83–97.

37. Engel N, Thorsen-Syen JL, Bartolomei MS. CTCF binding sites promote transcription initiation and prevent DNA methylation on the maternal allele at the imprinted H19/lifg2 locus. Hum Mol Genet. 2006;15(19):2945–54.

38. Vostrov AA, Quitschke WW. The zinc finger protein CTCF binds to the APRIBeta domain of the amyloid beta-protein precursor promoter. Evidence for a role in transcriptional activation. J Biol Chem. 1993;268(25):13353–9.

39. Xu J, Huo D, Chen Y, Nwachukwu C, Collins C, Collawn C, et al. CpG island methylation affects accessibility of the proximal BRCAl promoter to transcription factors. Cancer Bass Res Treat. 2010;120(3):593–601.

40. Lobanenkov WV, Nicolas RH, Adler W, Paterson H, Klenova EM, Polotskaja AV, et al. A novel sequence-specific DNA binding protein which interacts with three regularly spaced direct repeats of the CTCF-motif in the 5′flanking sequence of the chicken c-myc gene. Oncogene. 1990;5(2):1743–53.

41. Renaud S, Loukinov D, Collins C, Rowell J, et al. CTCF binding sites promote transcription insulation by CCCTC-binding factor. Nature. 2008;450(7165):838–43.

42. Farrar D, Rai S, Chernukhin I, Yammine S, et al. Mutation analysis of the poly(ADP-ribosyl)ation sites of the transcription factor CTCF provides an insight into the mechanism of its regulation by poly(ADP-)ribosylation. Mol Cell Biol. 2010;30(3):1199–216.

43. Engel N, Thorsen-Syen JL, Bartolomei MS. CTCF binding sites promote transcription initiation and prevent DNA methylation on the maternal allele at the imprinted H19/lifg2 locus. Hum Mol Genet. 2006;15(19):2945–54.

44. Vostrov AA, Quitschke WW. The zinc finger protein CTCF binds to the APBbeta domain of the amyloid beta-protein precursor promoter. Evidence for a role in transcriptional activation. J Biol Chem. 1993;268(25):13353–9.

45. Xu J, Huo D, Chen Y, Nwachukwu C, Collins C, Collawn C, et al. CpG island methylation affects accessibility of the proximal BRCAl promoter to transcription factors. Cancer Bass Res Treat. 2010;120(3):593–601.

46. Lobanenkov WV, Nicolas RH, Adler W, Paterson H, Klenova EM, Polotskaja AV, et al. A novel sequence-specific DNA binding protein which interacts with three regularly spaced direct repeats of the CTCF-motif in the 5′flanking sequence of the chicken c-myc gene. Oncogene. 1990;5(2):1743–53.

47. Renaud S, Loukinov D, Bosman FT, Lobanenkov V, Benhattar J. CTCF binds the proximal exonic region of hTERT and inhibits its transcription. Nucleic Acids Res. 2005;33(21):6850–60.

48. Bell AC, West AG, Felsenfeld G. The protein CTCF is required for the enhancer blocking activity of vertebrate insulators. Cell. 1999;98(4):823–96.
61. Zampieri M, Guastafierro T, Calabrese R, Ciccarone F, Bacalini MG, Reale A, et al. ADP-ribose polymers localized on Ctcf-Parp1-Dnmt1 complex prevent methylation of Ctcf target sites. Biochem J. 2012;441(2):645–52.

62. Herold M, Bartkuhn M, Renkawitz R. CTCF: insights into insulator function during development. Development. 2012;139(6):1045–57.

63. Ong CT, Corces VG. CTCF: an architectural protein bridging genome topology and function. Nat Rev Genet. 2014;15(4):234–46.

64. Martin-Kleiner I. BORIS in human cancers – a review. Eur J Cancer. 2012;48(6):929–35.

65. Marshall AD, Bailey CG, Rasko JE. CTCF and BORIS in genome regulation and cancer. Curr Opin Genet Dev. 2014;24:8–15.

66. Nguyen P, Cui HM, Bishk KS, Sun LC, Patel K, Lee RS, et al. CTCL/BORIS is a methylation-independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region. Cancer Res. 2008;68(14):5546–51.

67. Kitchen NS, Schoenherr CJ. Sumoylation modulates a domain in CTCF that activates transcription and decondenses chromatin. J Cell Biochem. 2010;111(3):665–75.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit